Alligator Announces Poster Presentation on OPTIMIZE-1 at SITC Virtual Annual Meeting 2021
Poster presentation to highlight the design of Optimize-1, evaluating mitazalimab in combination with chemotherapy in patients with metastat ...
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
Data support Advancement into the Clinic Lund, Sweden, and Seattle Washington, November 12, 2021 – Alligator Bioscience AB (“Alligator”) and ...
The subscription period in Alligator Bioscience’s rights issue begins today
Today is the first day of the subscription period in Alligator Bioscience AB (publ)'s ("Alligator" or the "Company") rig ...
Alligator Bioscience to Participate in Upcoming Investor Conferences
Lund, Sweden, November 10, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Søren Bregenholt, Chief Executive Offi ...
Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HO ...
Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University Rotterdam
First Patient Dosed in Study Evaluating Mitazalimab in Combination with Cancer Vaccine for Patients with Pancreatic Cancer Lund, Sweden, N ...
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
Today, on 8 November 2021, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follow ...
Nomination Committee appointed in respect of AGM 2022 in Alligator Bioscience AB
Lund, Sweden, November 3, 2021– Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation ...
Alligator enters into agreements on subscription commitments with board members and senior executives
The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or "the Company") has previously, subject to approval ...